FDA Removes Black-Box Warnings From Estrogen-Containing Menopause HT (Nov 2025)

Tier 1: Established: peer-reviewed research or government health authority
Publisher: CBS News (HealthWatch) – FDA Commissioner interview · Published: November 10, 2025 · Accessed: August 26, 2026

Visit the source ↗

Claims this source supports

• The FDA will remove the black-box warning labels on many hormone therapy drugs used for menopause and perimenopause symptoms, including medicines containing both estrogen and progesterone, systemic estrogen, and topical estrogen (CBS News, Nov 10 2025, FDA Commissioner Dr. Marty Makary in exclusive interview).
• The black-box warnings were based on what many experts now consider flawed research from the 2002 Women's Health Initiative, which overstated breast-cancer risks because the data focused on older women; more recent studies show benefits outweigh risks for many women when hormone therapy is used in the early years of menopause, before age 60 (CBS News, Nov 10 2025).
• FDA Commissioner Makary called the demonization of menopause hormone therapy 'an American tragedy' and 'one of the biggest mistakes in modern medicine,' describing a 'fear machine' and 'groupthink' among doctors after the 2002 study (CBS News, Nov 10 2025).
• Makary estimated 50 to 70 million women over the last 23 years were denied hormone replacement therapy because of the dogma, and said the change ends a decades-long 'fear machine' (CBS News, Nov 10 2025).
• Reported benefits of hormone therapy include reducing risk of heart attacks (leading cause of death in women), lowering risk of cognitive decline or Alzheimer's, and preventing osteoporosis and hip fractures (CBS News, Nov 10 2025, citing the Endocrine Society on menopause-related bone loss).
• Hormone therapy can ease menopause symptoms including hot flashes, insomnia, night sweats, mood swings, joint pain, and weight gain, which can be debilitating (CBS News, Nov 10 2025).